These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21748859)

  • 1. Aminoindanes--the next wave of 'legal highs'?
    Sainsbury PD; Kicman AT; Archer RP; King LA; Braithwaite RA
    Drug Test Anal; 2011; 3(7-8):479-82. PubMed ID: 21748859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Aminoindanes: A Summary of Existing Knowledge.
    Pinterova N; Horsley RR; Palenicek T
    Front Psychiatry; 2017; 8():236. PubMed ID: 29204127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects.
    Coppola M; Mondola R
    Toxicol Lett; 2013 Mar; 218(1):24-9. PubMed ID: 23347877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update.
    Corkery JM; Elliott S; Schifano F; Corazza O; Ghodse AH
    Hum Psychopharmacol; 2013 Jul; 28(4):345-55. PubMed ID: 23881883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist.
    Gibbons S
    Clin Toxicol (Phila); 2012 Jan; 50(1):15-24. PubMed ID: 22248120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites.
    Židková M; Linhart I; Balíková M; Himl M; Váňa L; Vetýška M; Páleníček T; Lhotková E; Dušek M
    Xenobiotica; 2017 Jun; 47(6):505-514. PubMed ID: 27401914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.
    Gallagher CT; Assi S; Stair JL; Fergus S; Corazza O; Corkery JM; Schifano F
    Hum Psychopharmacol; 2012 Mar; 27(2):106-12. PubMed ID: 22389075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives.
    Simmler LD; Rickli A; Schramm Y; Hoener MC; Liechti ME
    Biochem Pharmacol; 2014 Mar; 88(2):237-44. PubMed ID: 24486525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GHB and synthetic cathinones: clinical effects and potential consequences.
    Karila L; Reynaud M
    Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas chromatography-mass spectrometry of eight aminoindanes: 2-Aminoindane, N-methyl-2-, 5-methoxy-, 5-methoxy-6-methyl-, 4,5-methylenedioxy-, 5,6-methylenedioxy- and 5-iodo-2-aminoindane, and rasagiline.
    Rose AR; Staretz ME; Joshi M; Wood M; Brettell TA
    Rapid Commun Mass Spectrom; 2021; 35(24):e9207. PubMed ID: 34599535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research chemicals marketed as legal highs: the case of pipradrol derivatives.
    Coppola M; Mondola R
    Toxicol Lett; 2012 Jul; 212(1):57-60. PubMed ID: 22564760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keeping pace with NPS releases: fast GC-MS screening of legal high products.
    Elie MP; Elie LE; Baron MG
    Drug Test Anal; 2013 May; 5(5):281-90. PubMed ID: 23297247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the anorectic and motor activity effects of some aminoindanes, 2-aminotetralin and amphetamine in the rat.
    Mrongovius RI; Bolt AG; Hellyer RO
    Clin Exp Pharmacol Physiol; 1978; 5(6):635-40. PubMed ID: 719961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence and properties of spice and bath salts: a medicinal chemistry perspective.
    Lewin AH; Seltzman HH; Carroll FI; Mascarella SW; Reddy PA
    Life Sci; 2014 Feb; 97(1):9-19. PubMed ID: 24113072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central cyanosis on a psychiatric unit treated at the Salford Royal Hospital.
    Green D; Barry P; Green HD
    Thorax; 2014 Dec; 69(12):1157-8. PubMed ID: 25063354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GC-MS analysis of eight aminoindanes using three derivatization reagents.
    Rose AR; Joshi M; Staretz ME; Wood M; Brettell TA
    J Forensic Sci; 2023 Jul; 68(4):1148-1161. PubMed ID: 37282977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical analysis of national policy relating to legal highs.
    Sarpong I; Jones F
    Nurs Stand; 2014 Sep; 28(52):35-41. PubMed ID: 25159975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
    Rychert M; Wilkins C; Witten K
    Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones.
    Araújo AM; Valente MJ; Carvalho M; Dias da Silva D; Gaspar H; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
    Arch Toxicol; 2015 May; 89(5):757-71. PubMed ID: 24903018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.